Top Page
China Isotope & Radiation Corp.
(1763)
China Isotope & Radiation Corp. (1763) vs. iShares MSCI Hong Kong ETF (EWH)
China Isotope & Radiation Corp. Business Overview & Revenue Model
China Isotope & Radiation Corp. Financial Statement Overview
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 7.57B | 6.63B | 6.15B | 5.14B | 4.27B | Gross Profit |
| 3.68B | 3.48B | 3.51B | 3.24B | 2.62B | EBIT |
| 1.09B | 941.60M | 873.66M | 742.85M | 580.55M | EBITDA |
| 1.28B | 1.22B | 1.05B | 901.43M | 717.43M | Net Income Common Stockholders |
| 406.64M | 370.97M | 392.27M | 335.75M | 213.58M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 2.63B | 2.94B | 2.95B | 2.79B | 2.59B | Total Assets |
| 14.77B | 13.19B | 11.69B | 10.47B | 9.19B | Total Debt |
| 2.57B | 1.70B | 884.86M | 856.63M | 749.64M | Net Debt |
| -58.08M | -1.18B | -2.04B | -1.89B | -1.81B | Total Liabilities |
| 7.02B | 6.05B | 5.13B | 4.44B | 3.68B | Stockholders Equity |
| 5.01B | 4.69B | 4.47B | 4.18B | 3.89B |
| Cash Flow | Free Cash Flow | |||
| 142.48M | -812.66M | 328.66M | 366.59M | -118.01M | Operating Cash Flow |
| 142.48M | 84.96M | 862.66M | 794.31M | 291.91M | Investing Cash Flow |
| 0.00 | -429.88M | -506.62M | -907.36M | -423.90M | Financing Cash Flow |
| 0.00 | 484.37M | -291.50M | -97.44M | -156.25M |
China Isotope & Radiation Corp. Technical Analysis
China Isotope & Radiation Corp. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | HK$57.51B | 7.53 | 9.19% | 4.01% | -3.94% | -23.48% | |
74 Outperform | $32.28B | 11.57 | 14.56% | 4.18% | -5.37% | 6.28% | |
73 Outperform | HK$4.75B | 10.78 | 8.40% | 4.54% | 12.41% | ― | |
72 Outperform | $992.23B | 6.79 | 7.45% | 11.71% | 37.04% | ||
66 Neutral | $89.24B | 47.03 | 6.14% | 12.58% | 7.63% | -24.23% | |
65 Neutral | HK$65.06B | 13.78 | 6.22% | 1.93% | -2.82% | 11.93% | |
53 Neutral | $5.22B | 3.33 | -44.36% | 7.55% | 16.78% | -0.12% |
China Isotope & Radiation Corp. Corporate Events
China Isotope & Radiation Corporation announced a final cash dividend of RMB 0.309 per share for the year ended December 31, 2024, with payment scheduled for August 1, 2025. This announcement reflects the company’s stable financial performance and commitment to returning value to shareholders, potentially strengthening its position in the nuclear technology sector.
China Isotope & Radiation Corporation has announced proposed amendments to its Articles of Association, the Rules of Procedures of the Shareholders’ General Meeting, and the Rules of Procedures for the Board. These changes are in response to recent regulatory updates and are aimed at aligning the company’s governance documents with new legal and listing requirements. The amendments are subject to shareholder approval in upcoming meetings, and are intended to ensure compliance with evolving regulations, potentially impacting the company’s operational governance and stakeholder engagement.
China Isotope & Radiation Corporation announced the resignation of Ms. Liu Xiuhong from her position as a non-executive director due to a change in work arrangements. The company has proposed the appointment of Ms. Ma Xiaoyu as an executive director, pending shareholder approval. Ms. Ma brings extensive experience in nuclear technology application and international cooperation, having held significant roles within the China National Nuclear Corporation. Her appointment is expected to strengthen the company’s strategic positioning in the nuclear technology sector and enhance its market development efforts.
China Isotope & Radiation Corporation has announced the composition of its board of directors, detailing the roles and functions of each member. The board includes executive, non-executive, and independent non-executive directors, who are also part of various committees such as the Nomination Committee, Remuneration and Appraisal Committee, Audit and Risk Management Committee, Strategy Committee, Legal Affairs Committee, and Science and Technology Innovation Committee. This announcement reflects the company’s structured governance approach and highlights the diverse expertise of its board members, potentially strengthening its strategic and operational decision-making processes.
China Isotope & Radiation Corporation announced its annual financial results for the year ended December 31, 2024, showing a significant increase in revenue and profit compared to the previous year. The company’s revenue rose to RMB 7.57 billion, with a gross profit of RMB 3.68 billion, reflecting strong operational performance and market demand, which positively impacts its industry positioning and stakeholder interests.
China Isotope & Radiation Corp. announced a capital increase for its subsidiary, Sichuan Tongyuan, involving contributions from 404 Chengdu and Chengdu NPIC. This transaction will raise Sichuan Tongyuan’s registered capital from RMB100 million to RMB123.46 million, with CNGT retaining an 81% stake, while 404 Chengdu and Chengdu NPIC will hold 10% and 9% respectively. This move, categorized as a connected transaction under Hong Kong’s Listing Rules, reflects strategic financial restructuring within the company, potentially enhancing its operational capacity and market positioning.
China Isotope & Radiation Corporation announced that its subsidiary, CNNC Accuray, received 19 out of 28 deployment licenses for high-end radiotherapy equipment, specifically the CyberKnife, from the National Health Commission. This significant allocation is expected to expand CIRC’s market share and positively impact its operating results, reflecting strong industry and customer recognition.
China Isotope & Radiation Corporation has announced an upcoming board meeting scheduled for March 28, 2025, to review and approve the annual financial results for 2024 and discuss the potential recommendation of a final dividend. This meeting is significant as it will provide insights into the company’s financial health and strategic decisions, potentially impacting stakeholders and the company’s market positioning.
China Isotope & Radiation Corporation (CIRC) has announced the signing of an equipment supply contract for an irradiation station in Bangladesh. This project, with a capacity of 1 million curies, aims to enhance the quality and production capabilities of medical products in Bangladesh, thereby supporting the local medical industry. The successful acquisition of this project demonstrates CIRC’s ability to overcome technical challenges and strengthens its market presence in Bangladesh, setting a precedent for further international expansion.